Trevena Inc. (NASDAQ: TRVN) stock declined by 8.09% at last close whereas the TRVN stock-price gains by 8.8% in the after-hours trading. Trevena, Inc. is a pharmaceutical firm specializing on the discovery and marketing of novel treatments for people suffering from CNS diseases.
TRVN stock, Recent Development
The first COVID-19 patient has been recruited in the NIH-funded ACTIV-4 Host Tissue study, according to Trevena.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The ACTIV-4 Host Tissue study is evaluating four experimental medicines to treat COVID-19-induced dysregulation of the renin-angiotensin-aldosterone system (RAAS) and immune system. TRV027 is a new AT1 receptor-specific agonist that binds to AT1 receptor activity in the RAAS and rebalances it. It works by inhibiting the destructive route that causes acute lung problems and irregular blood clotting while stimulating the cellular pathway that focuses reparative activities that enhance lung function and boost anti-inflammatory efficacy.
Approximately 1,600 patients will be enrolled in the research, which will take place at more than 50 locations across the United States. TRV027 is one of the first research arms to be added to the trial, and other study arms will be added over time. The effect of each treatment on recovery, supplementary oxygen usage, the requirement for mechanical ventilation, organ failure, and mortality is being assessed in this study.
Carrie Bourdow, President and CEO of TRVN stock stated,
COVID-19 has no one cure, and they are proud to be a part of the worldwide effort to combat the epidemic and reduce its long-term effects on populations. TRV027 is one of the first active treatment arms accessible for patient randomization, and he is delighted that patients are already being recruited in this trial.
Sean Collins, Principal Investigator of the ACTIV-4 Host Tissue trial commented,
The discovery of treatments to counteract the coronavirus’s vascular, fibrotic, and inflammatory effects remains a major goal as the COVID-19 pandemic progresses. He added that he is thrilled to report that they’ve recruited their first patient in the ACTIV-4 Host Tissue study, and he is excited to learn more about TRV027’s ability to regulate the RAAS and enhance outcomes for COVID-19 patients.